Taken together, these results highlight IL-6R as a key regulator of Th17 cell metabolism via metabolic mediators that can be selectively targeted for the treatment of IL-6-associated pathologies such as autoimmune disease and infection-associated inflammation. Here, IL6 is linked to infection.